## National Board of Examinations

Question Paper Name :DNB Pathology Paper2Subject Name :DNB Pathology Paper2Creation Date :2024-05-16 18:57:02Duration :180Share Answer Key With Delivery Engine :NoActual Answer Key :No

## **DNB Pathology Paper2**

**Group Number:** Group Id: 3271872011 **Group Maximum Duration:** 0 180 **Group Minimum Duration: Show Attended Group?:** No **Edit Attended Group?:** No **Group Marks:** 100 Is this Group for Examiner?: No **Examiner permission: Cant View Show Progress Bar?:** No

## **DNB Pathology Paper2**

**Section Id:** 3271872014

Section Number: 1

Section type: Offline

Mandatory or Optional: Mandatory

Number of Questions to be attempted: 10

Section Marks: 100

**Enable Mark as Answered Mark for Review and** 

**Clear Response:** 

Yes

**Maximum Instruction Time:** 0

Sub-Section Number: 1

**Sub-Section Id:** 3271872018

**Question Shuffling Allowed:** No

Is Section Default?: null

Question Number: 1 Question Id: 32718719752 Question Type: SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Describe Sydney system for reporting lymph node cytopathology. [10]

Question Number: 2 Question Id: 32718719753 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

a) CISH. [5]

b) Targeted sequencing. [5]

Question Number: 3 Question Id: 32718719754 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Describe the technique & utility of liquid based cytology in serous fluids for malignancy. [10]

Question Number: 4 Question Id: 32718719755 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Discuss the role of EUS FNA in the evaluation of mediastinal masses. [10]

Question Number: 5 Question Id: 32718719756 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

a) CRISPR technology. [5]

b) Amplification refractory mutation system (ARMS). [5]

Question Number: 6 Question Id: 32718719757 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Describe MMR immunohistochemistry in colon cancer & its role in guiding therapy. [10]

Question Number: 7 Question Id: 32718719758 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

Discuss the 2022 WHO classification of Neuroendocrine Neoplasms. [10]

Question Number: 8 Question Id: 32718719759 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

a) Role of immunocytochemistry in lung cancer. [5]

b) FNAC of cystic pancreatic lesions. [5]

Question Number: 9 Question Id: 32718719760 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

a) Role of cytology in diseases of testis. [5]

b) Specimen preparation techniques in urine cytology. [5]

Question Number: 10 Question Id: 32718719761 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

**Correct Marks: 10** 

NGS based tumor panel testing and its role in breast cancer. [10]